ABBVIE
- Country
- π«π·France
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 518
- Registration Number
- NCT04492020
- Locations
- πΊπΈ
WR-ClinSearch /ID# 238287, Chattanooga, Tennessee, United States
πΊπΈTidewater Integr Med Research /ID# 236867, Virginia Beach, Virginia, United States
πΊπΈWr-Pri Llc /Id# 236007, Los Alamitos, California, United States
Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1
- Registration Number
- NCT04480086
- Locations
- πΊπΈ
Stony Brook University Hospital /ID# 222653, Stony Brook, New York, United States
π°π·Inje University Busan Paik Hospital /ID# 224043, Busan, Korea, Republic of
πΊπΈUC Health - Cincinnati /ID# 224079, Cincinnati, Ohio, United States
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 6
- Registration Number
- NCT04477486
- Locations
- π―π΅
Yamagata University Hospital /ID# 221573, Yamagata-shi, Yamagata, Japan
π―π΅Aichi Cancer Center Hospital /ID# 221565, Nagoya-shi, Aichi, Japan
π―π΅Okayama University Hospital /ID# 221623, Okayama-shi, Okayama, Japan
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 252
- Registration Number
- NCT04472598
- Locations
- π¨π¦
Lakeridge Health - Oshawa /ID# 222080, Oshawa, Ontario, Canada
πΊπΈIndiana Blood & Marrow Transpl /ID# 221586, Indianapolis, Indiana, United States
πΊπΈUniversity of Texas MD Anderson Cancer Center /ID# 217994, Houston, Texas, United States
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 295
- Registration Number
- NCT04468984
- Locations
- πΊπΈ
Hospital of the University of Pennsylvania /ID# 219001, Philadelphia, Pennsylvania, United States
π¨π¦Princess Margaret Cancer Centre /ID# 253942, Toronto, Ontario, Canada
π¦πΉKlinikum Wels-Grieskirchen GmbH /ID# 220915, Wels, Oberoesterreich, Austria
A Study to Evaluate Pregnancy Outcomes in Females Treated With Oral Elagolix Tablets and Capsules
- Conditions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 584
- Registration Number
- NCT04464187
- Locations
- πΊπΈ
Iqvia /Id# 240918, Durham, North Carolina, United States
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 21
- Registration Number
- NCT04454658
- Locations
- π¦πΊ
Royal Perth Hospital /ID# 241678, Perth, Western Australia, Australia
πΊπΈThe Mount Sinai Hospital /ID# 221549, New York, New York, United States
πΊπΈUniversity of Oklahoma, Stephenson Cancer Center /ID# 224095, Oklahoma City, Oklahoma, United States
Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 119
- Registration Number
- NCT04451720
- Locations
- π―π΅
St.Luke's International Hospital /ID# 219019, Chuo-ku, Tokyo, Japan
π―π΅Tokyo Medical University Hospital /ID# 218893, Shinjuku-ku, Tokyo, Japan
π―π΅Seibo Hospital /ID# 221691, Shinjuku-ku, Tokyo, Japan
A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State
- Conditions
- Interventions
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 185
- Registration Number
- NCT04451772
- Locations
- πΊπΈ
Deerbrook Medical Associates /ID# 227330, Libertyville, Illinois, United States
π¦π·Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich /ID# 222569, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina
π¦π·Instituto CAICI S.R.L /ID# 221892, Rosario, Santa Fe, Argentina
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 186
- Registration Number
- NCT04437433
- Locations
- π―π΅
Takanoko Hospital /ID# 232723, Matsuyama-shi, Ehime, Japan
π―π΅Mito Kyodo General Hospital /ID# 232990, Mito-shi, Ibaraki, Japan
π―π΅Saitama Neuropsychiatric Institute /Id# 232711, Saitama-shi, Saitama, Japan